Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity

Carlos M. B. P. Goncalves de Azavedo; Kenneth R Watterson; Ed T Wargent; Steffen V F Hansen; Brian D Hudson; Małgorzata A Kępczyńska; Julia Dunlop; Bharat Shimpukade; Elisabeth Christiansen; Graeme Milligan; Claire J Stocker; Trond Ulven

doi:10.1021/acs.jmedchem.6b00685

Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity

Carlos M. B. P. Goncalves de Azavedo, Kenneth R Watterson, Ed T Wargent, Steffen V F Hansen, Brian D Hudson, Małgorzata A Kępczyńska, Julia Dunlop, Bharat Shimpukade, Elisabeth Christiansen, Graeme Milligan, Claire J Stocker, Trond Ulven

54 Citations (Scopus)

Abstract

The free fatty acid receptor 4 (FFA4 or GPR120) has appeared as an interesting potential target for the treatment of metabolic disorders. At present, most FFA4 ligands are carboxylic acids that are assumed to mimic the endogenous long-chain fatty acid agonists. Here, we report preliminary structure-activity relationship studies of a previously disclosed non-acidic sulfonamide FFA4 agonist. Mutagenesis studies indicate that the compounds are orthosteric agonists despite the absence of a carboxylate function. The preferred compounds showed full agonist activity on FFA4 and complete selectivity over FFA1, although a significant fraction of these non-carboxylic acids also showed partial antagonistic activity on FFA1. Studies in normal and diet-induced obese (DIO) mice with the preferred compound 34 showed improved glucose tolerance after oral dosing in an oral glucose tolerance test. Chronic dosing of 34 in DIO mice resulted in significantly increased insulin sensitivity and a moderate but significant reduction in bodyweight, effects that were also present in mice lacking FFA1 but absent in mice lacking FFA4.

Original language	English
Journal	Journal of Medicinal Chemistry
Volume	59
Issue number	19
Pages (from-to)	8868-8878
Number of pages	11
ISSN	0022-2623
DOIs	https://doi.org/10.1021/acs.jmedchem.6b00685
Publication status	Published - 13 Oct 2016
Externally published	Yes

Access to Document

10.1021/acs.jmedchem.6b00685

Cite this

Goncalves de Azavedo, C. M. B. P., Watterson, K. R., Wargent, E. T., Hansen, S. V. F., Hudson, B. D., Kępczyńska, M. A., Dunlop, J., Shimpukade, B., Christiansen, E., Milligan, G., Stocker, C. J., & Ulven, T. (2016). Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity. Journal of Medicinal Chemistry, 59(19), 8868-8878. https://doi.org/10.1021/acs.jmedchem.6b00685

@article{694e2deb627f4ebda14d8a4631550d2f,

title = "Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity",

abstract = "The free fatty acid receptor 4 (FFA4 or GPR120) has appeared as an interesting potential target for the treatment of metabolic disorders. At present, most FFA4 ligands are carboxylic acids that are assumed to mimic the endogenous long-chain fatty acid agonists. Here, we report preliminary structure-activity relationship studies of a previously disclosed non-acidic sulfonamide FFA4 agonist. Mutagenesis studies indicate that the compounds are orthosteric agonists despite the absence of a carboxylate function. The preferred compounds showed full agonist activity on FFA4 and complete selectivity over FFA1, although a significant fraction of these non-carboxylic acids also showed partial antagonistic activity on FFA1. Studies in normal and diet-induced obese (DIO) mice with the preferred compound 34 showed improved glucose tolerance after oral dosing in an oral glucose tolerance test. Chronic dosing of 34 in DIO mice resulted in significantly increased insulin sensitivity and a moderate but significant reduction in bodyweight, effects that were also present in mice lacking FFA1 but absent in mice lacking FFA4.",

author = "{Goncalves de Azavedo}, {Carlos M. B. P.} and Watterson, {Kenneth R} and Wargent, {Ed T} and Hansen, {Steffen V F} and Hudson, {Brian D} and K{\c e}pczy{\'n}ska, {Ma{\l}gorzata A} and Julia Dunlop and Bharat Shimpukade and Elisabeth Christiansen and Graeme Milligan and Stocker, {Claire J} and Trond Ulven",

year = "2016",

month = oct,

day = "13",

doi = "10.1021/acs.jmedchem.6b00685",

language = "English",

volume = "59",

pages = "8868--8878",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "19",

}

TY - JOUR

T1 - Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity

AU - Goncalves de Azavedo, Carlos M. B. P.

AU - Watterson, Kenneth R

AU - Wargent, Ed T

AU - Hansen, Steffen V F

AU - Hudson, Brian D

AU - Kępczyńska, Małgorzata A

AU - Dunlop, Julia

AU - Shimpukade, Bharat

AU - Christiansen, Elisabeth

AU - Milligan, Graeme

AU - Stocker, Claire J

AU - Ulven, Trond

PY - 2016/10/13

Y1 - 2016/10/13

N2 - The free fatty acid receptor 4 (FFA4 or GPR120) has appeared as an interesting potential target for the treatment of metabolic disorders. At present, most FFA4 ligands are carboxylic acids that are assumed to mimic the endogenous long-chain fatty acid agonists. Here, we report preliminary structure-activity relationship studies of a previously disclosed non-acidic sulfonamide FFA4 agonist. Mutagenesis studies indicate that the compounds are orthosteric agonists despite the absence of a carboxylate function. The preferred compounds showed full agonist activity on FFA4 and complete selectivity over FFA1, although a significant fraction of these non-carboxylic acids also showed partial antagonistic activity on FFA1. Studies in normal and diet-induced obese (DIO) mice with the preferred compound 34 showed improved glucose tolerance after oral dosing in an oral glucose tolerance test. Chronic dosing of 34 in DIO mice resulted in significantly increased insulin sensitivity and a moderate but significant reduction in bodyweight, effects that were also present in mice lacking FFA1 but absent in mice lacking FFA4.

AB - The free fatty acid receptor 4 (FFA4 or GPR120) has appeared as an interesting potential target for the treatment of metabolic disorders. At present, most FFA4 ligands are carboxylic acids that are assumed to mimic the endogenous long-chain fatty acid agonists. Here, we report preliminary structure-activity relationship studies of a previously disclosed non-acidic sulfonamide FFA4 agonist. Mutagenesis studies indicate that the compounds are orthosteric agonists despite the absence of a carboxylate function. The preferred compounds showed full agonist activity on FFA4 and complete selectivity over FFA1, although a significant fraction of these non-carboxylic acids also showed partial antagonistic activity on FFA1. Studies in normal and diet-induced obese (DIO) mice with the preferred compound 34 showed improved glucose tolerance after oral dosing in an oral glucose tolerance test. Chronic dosing of 34 in DIO mice resulted in significantly increased insulin sensitivity and a moderate but significant reduction in bodyweight, effects that were also present in mice lacking FFA1 but absent in mice lacking FFA4.

U2 - 10.1021/acs.jmedchem.6b00685

DO - 10.1021/acs.jmedchem.6b00685

M3 - Journal article

SN - 0022-2623

VL - 59

SP - 8868

EP - 8878

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 19

ER -

Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity

Abstract

Access to Document

Fingerprint

Cite this